新冠疫苗追加劑在長新冠的保護力簡介

Covid-19 Vaccine Booster Protection for Long COVID: A Mini Review

新冠肺炎目前還處在廣泛流行的狀況。在以色列，證明施打新冠疫苗追加劑可以明顯的降低Delta或者Omicron變異株的突破性傳染。可是，世界衛生組織和某些國家認為，對於疫苗資源相對缺少的地方而言，準備疫苗做多次的追加劑注射是沒有必要而且不公平的。另外，當患者從新冠肺炎的急性期復原後，可能會產生有害的後遺症，而這種新的疾病狀況，目前稱為後新冠肺炎症候群或是長新冠。部分研究認為新冠疫苗有助於保護對抗長新冠，但並沒有獲得一致的共識。這篇論文主要在簡介研究長新冠與追加劑疫苗相關性的報告，我們認為，不論在感染新型冠狀病毒之前或之後，新冠疫苗確實降低獲得長新冠的風險，而且有必要施打追加劑，還有需要更多的基礎研究釐清疫苗對於長新冠的保護機制。

The coronavirus disease 2019 (COVID-19) is still in a global pandemic state. It has been overwhelmingly demonstrated that Delta or Omicron breakthrough infection can be considerably mitigated by a third booster shot, as shown, for example, by the rapid success of the booster rollout in Israel. However, the case has been argued through the World Health Organization and elsewhere that stockpiling of vaccine doses for additional boosts when much of the world is in danger, not yet having accessed a first dose, is both unnecessary and unethical. Although patients recover from acute symptoms, COVID-19 might have detrimental sequelae even after the post-acute phase, depicting a new pathological condition—“post-COVID-19 syndrome (PCS)”or“long COVID”. Some studies have reported that COVID-19 vaccines have a protective effect against long COVID. However, the conclusions of the studies on the effect of COVID-19 vaccines on long COVID have not been consistent. This study aimed to systematically review relevant studies in the real world and explore the relationship between booster vaccination and long COVID. Our study shows that COVID-19 vaccines have an effect on reducing the risk of long COVID in patients vaccinated before or after SARS-CoV-2 infection/COVID-19. We suggest that the vaccination rate should be improved, especially for booster shots. More studies are needed to explore the basic mechanisms of the protective effects of COVID-19 vaccines on long COVID in the future.